An Open-label Extension of Study AC-066A401 Investigating the Safety and Tolerability of ACT-385781A Compared to Flolan in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH)
Latest Information Update: 05 Aug 2019
At a glance
- Drugs Epoprostenol (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms EPITOME-1 Ext
- Sponsors Actelion Pharmaceuticals
Most Recent Events
- 05 Aug 2019 New trial record